ADAM17 and rheumatoid arthritis: Thanks to its broader inhibitory profile, TIMP-3 has been proven beneficial in diseases such as rheumatoid arthritis [26], which is majorly driven by an excess activity of TIMP-3 target ADAM17, and osteoarthritis, which is characterized by cartilage breakdown due to ADAMTS-4 and -5 [27].